This study is intended to provide a definitive test of the hypothesis that elevating
sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in
the CNS will result in measurable improvements in core symptoms of autism in young
individuals, under age 6 years. The study will entail a double-blind, placebo-controlled
16-week intervention.